Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...

Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...

Neoadjuvant disitamab vedotin plus perioperative toripalimab showed promising efficacy and acceptable safety in patients with HER2-expressing MIBC, according to Xinan Sheng, MD.

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...